Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • LRRK2
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

lrrk2 ser1292

" in TargetMol Product Catalog
  • Inhibitor Products
    5
    TargetMol | Activity
Enkephalin-leu, ala(2)-ser(6)-
T31631132930-82-6
Enkephalin-leu, ala(2)-ser(6)- is an active compound at the delta (non-complexed) opioid receptor.
  • $1,520
6-8 weeks
Size
QTY
LRRK2-IN-2
T638242641059-19-8
LRRK2-IN-2 is a selective, potent, and orally active LRRK2 inhibitor (IC50: 0.6 nM) that crosses the blood-brain barrier. LRRK2-IN-2 can be used to study Parkinson's disease.
  • $2,140
10-14 weeks
Size
QTY
LRRK2-IN-6
T62871
LRRK2-IN-6 (compound 22) is an orally active, selective leucine-rich repeat protein kinase 2 gene (LRRK2) inhibitor with blood-brain barrier permeability that inhibits GS LRRK2 (IC50: 4.6 μM) and WT LRRK2 (IC50: 49 μM). LRRK2-IN-6 exhibited an inhibitory effect on the autophosphorylation of LRRK2 Ser1292 and Ser925.
  • $1,520
10-14 weeks
Size
QTY
LRRK2-IN-5
T63057
LRRK2-IN-5 (compound 25) is an oral active, blood-brain barrier penetrating, selective leucine-rich repeat protein kinase 2 (LRRK2) inhibitor, which is effective for GS LRRK2 (IC50: 1.2 μM) and WT LRRK2 (IC50:16 μM) had inhibitory effects. LRRK2-IN-5 can inhibit the autophosphorylation of LRRK2 Ser1292 and Ser925.
  • $1,520
10-14 weeks
Size
QTY
GNE-9605
T17701536200-31-3
GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).
  • $32
In Stock
Size
QTY